ArticleBiomolecules & biomedicine2026
Indole-3-carbinol attenuates DNCB-induced atopic dermatitis in mice by reducing inflammation and IL-4/IL-13 expression.
Article in Biomolecules & biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD), commonly known as atopic eczema, is a chronic inflammatory skin disease. Indole-3-carbinol (I3C), a phytochemical naturally occurring in Brassica vegetables, has been traditionally used in folk medicine for inflammatory and metabolic disorders. This study investigated the immunomodulatory and anti-inflammatory effects of I3C in a mouse model of 1-chloro-2,4-dinitrobenzene (DNCB)-induced atopic dermatitis. Atopic dermatitis was induced by DNCB sensitization on days 0 and 3. Following disease confirmation on day 7, mice received daily oral or topical administrations of I3C or prednisolone from day 7 to day 19. Macroscopic evaluations included dorsal skin and ear thickness measurements. Histopathological changes were assessed using hematoxylin and eosin staining, and hematological parameters were also analyzed. Gene expression of interleukin (IL)-4 and IL-13 in ear tissue was quantified by real-time polymerase chain reaction (RT-qPCR). Computational molecular docking was performed to determine I3C's affinity for both cytokines. The data indicated that I3C attenuated DNCB-induced AD-like symptoms following both oral and topical administration. Treatment with I3C also resulted in reduced ear thickness. Hematological analysis revealed significantly decreased total leukocyte counts (TLC) and a general downward numerical trend in differential leukocyte count (DLC) parameters in I3C-treated groups. Histopathological evaluation confirmed that I3C ameliorated skin thickening and reduced inflammatory cell infiltration. Furthermore, IL-4 and IL-13 expression levels were decreased in I3C-treated groups. Molecular docking analysis demonstrated moderate binding affinities of -5.1 kcal/mol and -5.3 kcal/mol with IL-4 and IL-13, respectively. In conclusion, findings from this exploratory study suggest that I3C treatment ameliorated DNCB-induced atopic dermatitis in mice, evidenced by reductions in ear thickness and IL-4/IL-13 mRNA expression. Molecular docking analysis demonstrated moderate binding affinities of I3C toward IL-4 and IL-13, providing supportive evidence of potential ligand-protein interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.